文献速递白血病

上调的SPAG6通过调控EGFR家族表达的MYO1D促进急性髓系白血病进展

Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression.
PubMed 文献 · Blood Adv · 2022-01-01

研究探讨SPAG6在急性髓系白血病(AML)中的作用机制,发现SPAG6在AML中高表达且与预后负相关,体外促进白血病细胞增殖迁移和G1至S期细胞周期进展,体内低表达SPAG6减少白血病细胞增殖浸润并延长异种移植小鼠生存。SPAG6与MYO1D相互作用并促其转位至细胞膜,上调EGFR家族表达,激活PI3K/AKT和ERK信号通路,SPAG6可能成为AML治疗新靶点。

要点

  • SPAG6在AML中高表达,其上调与疾病预后负相关。
  • SPAG6体外促进白血病细胞增殖迁移及G1至S期进展,体内低表达延长异种移植小鼠生存。
  • SPAG6与MYO1D相互作用并促其转位至细胞膜,上调EGFR家族表达,激活PI3K/AKT和ERK通路。

核心结论

  • SPAG6在AML中高表达且与预后负相关,通过MYO1D调控EGFR家族表达及PI3K/AKT和ERK信号通路促进AML进展,可能成为AML治疗新靶点。

研究设计与样本

  • 基础研究,包括体外白血病细胞实验和体内异种移植肿瘤小鼠模型,采用免疫沉淀和质谱分析鉴定蛋白相互作用。

主要发现

  • SPAG6在AML中高表达,其上调与疾病预后负相关。
  • 体外SPAG6促进白血病细胞增殖和迁移,并促进细胞周期从G1期向S期进展。
  • 体内低表达SPAG6减少白血病细胞增殖和浸润,并延长异种移植肿瘤小鼠的生存。
  • 免疫沉淀和质谱分析显示SPAG6与MYO1D相互作用。
  • SPAG6过表达促进MYO1D转位至细胞膜,上调EGFR家族表达水平,进而促进AML进展。

临床怎么用

  • 原文结论提出SPAG6可能成为治疗AML的新靶基因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chromosomal aberrations and gene mutations have been considered to be the major reasons for high recurrence rates and poor survival among acute myeloid leukemia (AML) patients. However, the underlying molecular mechanism of AML gene mutation remains largely unclear. Here, we show that SPAG6 (sperm-associated antigen 6), one of the most markedly increased SPAG genes in AML, significantly contributed to the proliferation and migration of leukemic cells. SPAG6 was highly expressed in AML, and its upregulation was negatively correlated with the prognosis of the disease. In vitro, SPAG6 promoted the proliferation and migration of leukemia cells and promoted cell cycle progression from the G1 phase to the S phase. In vivo, low expression of SPAG6 reduced the proliferation and infiltration of leukemia cells and prolonged the survival of xenograft tumor mice. Furthermore, immunoprecipitation and mass spectrometry analysis showed that SPAG6 interacts with MYO1D (myosin 1D). Specifically, overexpression of SPAG6 promoted the translocation of MYO1D into the cell membrane, thus upgrading the expression level of the EGFR family and thereby promoting the progression of AML. Overall, our study found that SPAG6 combined with MYO1D and translocated MYO1D from the cytosol to the cytomembrane, which induced the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B) signaling and ERK (extracellular signal-regulated kinase) signaling pathway to regulate the growth and prognosis of AML. SPAG6 may become a new target gene for the treatment of AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mu J, Yuan P, Luo J, et al. Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression. Blood Adv. 2022. PMID: 35667090. doi:10.1182/bloodadvances.2021006920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。